Recursion Pharmaceuticals, Inc.
Every calculator, already run for RXRX
Open the full toolkit →You have the numbers on RXRX. Get the argument.
A written report on which of these readings actually decide the outcome for Recursion Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering RXRXAnalyst Price Target Disagreement for Recursion Pharmaceuticals, Inc.
Wall Street's bull case implies +161% from the current price; the bear case implies +4%. A 157% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for RXRX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4…
RXRX — frequently asked
Is RXRX a buy right now?
Wall Street's consensus rating on Recursion Pharmaceuticals, Inc. is none across 7 analysts, with a mean price target of $7.22 (+88% vs. the current $3.83). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is RXRX's next earnings date?
Recursion Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 4, 2026. A full RXRX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Recursion Pharmaceuticals, Inc.?
Analysts covering Recursion Pharmaceuticals, Inc. (RXRX) range from a bear-case target of $4.00 to a bull-case high of $10.00, with a mean consensus target of $7.22 across 6 analysts. The spread of $6.00 (157% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Recursion Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Recursion Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full RXRX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Recursion Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.